Featured Research

from universities, journals, and other organizations

EPO Prevents Chemotherapy Cardiotoxicity, Study Suggests

Date:
December 26, 2007
Source:
Society for Experimental Biology and Medicine
Summary:
The use of several chemotherapeutic agents in oncology is limited by their cardiac toxicity. Recent experimental studies suggest that recombinant human erythropoietin (rhEPO) can be considered as a protective agent against cardiac ischemic injury. Here we show that pretreatment by rhEPO protects myocardium against cardiotoxicity induced by acute doxorubicin or trastuzumab exposure, using the isolated rat heart model. Further clinical investigations are now needed to explore the potential benefit of rhEPO in oncology.

Researchers at the University of Grenoble, in France, have discovered that erythropoietin administration prevents acute cardiotoxic effects induced by doxorubicin and trastuzumab exposures. Although rare, cardiotoxicity is a serious complication of cancer treatment. Indeed, the use of chemotherapeutic agents such as anthracycline or trastuzumab in oncology is limited by their cardiac toxicity. Therefore, it is of interest to identify new protective agents preventing these adverse effects.

"The increasing use of doxorubicin and trastuzumab in adjuvant breast cancer therapy and the growing population of long-term pediatric cancer survivors mean that, more than ever, cardiotoxicity will continue to remain an important issue for oncology. Cardiomyopathy induced by chronic chemotherapy may result, at least in part, from acute cardiotoxic effects accompanying each drug exposure." said Professor Mireille Mousseau, head of the Department of Oncology.

The research team, led by Christophe Ribuot, a professor of pharmacology, explored the beneficial cardioprotective effect afforded by recombinant human erythropoietin (rhEPO) against various stresses, through experimental and clinical investigations.

"We observed for the first time that only a unique rhEPO administration prevents cardiac damage induced by an acute doxorubicin or trastuzumab exposure, using the isolated rat heart model." said the article's first author Amandine Ramond. "RhEPO administration could, therefore, be used during chemotherapy administration to reduce acute cardiotoxic effects accompanying each drug exposure and, potentially, to prevent long-term development of cardiomyopathy. Further clinical investigations are now needed to explore the potential benefit of rhEPO in oncology."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said "Amandine Ramond and her colleagues have provided an insightful study demonstrating that rhEPO can reduce the cardiotoxic effects of chemotherapeutic agents, doxorubicin and trastzumab, in a rat heart model. If rhEPO has similar effects on humans then this study will be of substantial benefit to cancer patients worldwide."

The research article describing this work entitled "Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts" will be featured in the January 2008 issue of Experimental Biology and Medicine.


Story Source:

The above story is based on materials provided by Society for Experimental Biology and Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Society for Experimental Biology and Medicine. "EPO Prevents Chemotherapy Cardiotoxicity, Study Suggests." ScienceDaily. ScienceDaily, 26 December 2007. <www.sciencedaily.com/releases/2007/12/071220123841.htm>.
Society for Experimental Biology and Medicine. (2007, December 26). EPO Prevents Chemotherapy Cardiotoxicity, Study Suggests. ScienceDaily. Retrieved April 25, 2014 from www.sciencedaily.com/releases/2007/12/071220123841.htm
Society for Experimental Biology and Medicine. "EPO Prevents Chemotherapy Cardiotoxicity, Study Suggests." ScienceDaily. www.sciencedaily.com/releases/2007/12/071220123841.htm (accessed April 25, 2014).

Share This



More Health & Medicine News

Friday, April 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Fungus Killing Bats, Spreading in US

Deadly Fungus Killing Bats, Spreading in US

AP (Apr. 24, 2014) A disease that has killed more than six million cave-dwelling bats in the United States is on the move and wildlife biologists are worried. White Nose Syndrome, discovered in New York in 2006, has now spread to 25 states. (April 24) Video provided by AP
Powered by NewsLook.com
Companies Ramp Up Wellness to Lower Health Costs

Companies Ramp Up Wellness to Lower Health Costs

AP (Apr. 24, 2014) That little voice telling you to exercise, get in shape and get healthy is probably coming from your boss. More companies are beefing up wellness programs to try and cut down their health care costs. (April 24) Video provided by AP
Powered by NewsLook.com
Blood From World's Oldest Woman Suggests Life Limit

Blood From World's Oldest Woman Suggests Life Limit

Newsy (Apr. 24, 2014) Scientists say for the extremely elderly, their stem cells might reach a state of exhaustion. This could limit one's life span. Video provided by Newsy
Powered by NewsLook.com
FDA Wants To Ban Sales Of E-Cigarettes To Minors

FDA Wants To Ban Sales Of E-Cigarettes To Minors

Newsy (Apr. 24, 2014) The Food and Drug Administration wants to crack down on the use of e-cigarettes, banning the sale of the product to minors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins